Resultado de búsqueda
Stereotactic body radiotherapy (SBRT) for patients with metastatic cancer, especially when characterised by a low tumour burden (ie, oligometastatic disease), receiving targeted therapy or immunotherapy has become a frequently practised and guideline-supported treatment strategy.
13 de sept. de 2022 · SBRT for oligometastatic lung cancer. The SBRT treatment strategy for pulmonary OMD from primary lung cancer is generally considered to be the same as for early-stage non-small cell lung cancer (NSCLC).
- 10.1007/s11604-022-01323-9
- 2022
- Jpn J Radiol. 2022; 40(10): 995-1005.
15 de jul. de 2021 · Lung metastases are widely accepted to be oligometastatic when five lesions or less occur separately in up to three organs. Stereotactic body radiation therapy (SBRT) is a noninvasive, safe, and effective treatment for metastatic lung disease in carefully selected patients.
- Enrique Gutiérrez, Enrique Gutiérrez, Irving Sánchez, Omar Díaz, Adrián Valles, Ricardo Balderrama, ...
- 10.3390/curroncol28040233
- 2021
- Curr Oncol. 2021 Aug; 28(4): 2560-2578.
15 de nov. de 2022 · Stereotactic body radiation therapy (SBRT) has proven to be a potential alternative to resection. This prospective phase 2 study aimed to assess the role of SBRT for patients with lung metastases. Methods and materials: Adult patients with up to 4 lung metastases (LMs) ≤5 cm in diameter and unsuitable for surgery were included.
- Patient Characteristics
- Tumor Characteristics and Treatment
- Local Control, Local Progression-Free Survival and Overall Survival
- Adverse Events
From 2010 to 2022, 18 patients treated to 26 metastatic lung sarcoma lesions with SBRT were included in this study. Patient characteristics are outlined in Table 1. Of the 18 patients, most were male (72%), had high grade primary sarcoma (66.7%), and had oligometastatic disease at the time of SBRT (72%). Median time from diagnosis to distant metast...
Characteristics of the lung lesions treated with SBRT are outlined in Table 2. The median number of lesions treated per patient was 1 (range 1–3 lesions). Histology of most lesions were liposarcoma (30.8%), followed by leiomyosarcoma (23.1%) and Ewing/Ewing-like sarcoma (15.4%). Most lesions were in the lower lung lobe (46.2%) and were treated to 5...
The 1- and 2-year local control rate were 100% and 96%, respectively. Of the 26 metastases, local failure occurred for one lesion (leiomyosarcoma) in a patient at 15.2 months after completion of SBRT to 54 Gy in 3 fractions. LPFS at 2-years was 95.5%. On univariable and multivariable analysis, LPFS was not significantly associated with gender (p = ...
Three patients (16.7%) developed side effects from SBRT and were treated to peripherally (2 patients) and centrally (1 patient) located lesions. All three developed grade 1 fatigue during treatment, however, this did not prevent any from performing their daily activities. One patient who received SBRT to a peripheral lung lesion developed grade 1 n...
25 de feb. de 2021 · All plans and clinical data were centrally collected. 27 patients from 8 centers have been amenable for evaluation: 12 with non-small-cell lung cancer, 16 with metastases, treated from 2009...
15 de jul. de 2021 · Current Evidence for Stereotactic Body Radiotherapy in Lung Metastases. by. Enrique Gutiérrez. 1,2, Irving Sánchez. 3, Omar Díaz. 3, Adrián Valles. 3, Ricardo Balderrama. 3, Jesús Fuentes. 3, Brenda Lara. 3, Cipatli Olimón. 3, Víctor Ruiz. 3, José Rodríguez. 3, Luis H. Bayardo. 3, Matthew Chan. 1,2, Conrad J. Villafuerte. 1,2, Jerusha Padayachee.
